Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4592 - Ostracism In Adolescent Cancer Patients And Predictors (OSTRACA Study): A Study Of The Palliative Care Working Committee Of The Turkish Oncology Group (TOG)

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Psychosocial Aspects of Cancer

Tumour Site

Presenters

Ali Alkan

Citation

Annals of Oncology (2018) 29 (suppl_8): viii557-viii561. 10.1093/annonc/mdy296

Authors

A. Alkan1, Z.G. Güç2, T. Şakalar3, G. Zengin4, A. Yaşar5, Y. Karakas6, T. Yavuzsen7, O.B. Oksuzoglu8, F. Çay Şenler9

Author affiliations

  • 1 Medical Oncology, Osmaniye Public Hospital, 80000 - Osmaniye/TR
  • 2 Medical Oncology, Dokuz Eylül University School of Medicine, 35000 - İzmir/TR
  • 3 Medical Oncology, Erciyer University School of Medicine, 80350 - Kayseri/TR
  • 4 Medical Oncology, Ankara Abdurrahman Yurtaslan Oncology Hospital, 06000 - Ankara/TR
  • 5 Medical Oncology, Ankara University School of Medicine, 06000 - Ankara/TR
  • 6 Medical Oncology, Hakkari Public Hospital, 6100 - HAkkari/TR
  • 7 Medical Oncology, Dokuz Eylul University School of Medicine, Institute of Oncology, 35340 - Izmir/TR
  • 8 Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Onkoloji Training and Research Hospital, 6200 - Ankara/TR
  • 9 Medical Oncology, Ankara University School of Medicine, 34000 - İstanbul/TR
More

Resources

Abstract 4592

Background

Ostracism is defined as being ignored or excluded by others. Being excluded during adolescence can result in various problem behaviors and emotional disturbances. The purpose of the study is to evaluate ostracism in adolescent cancer patients and define the predictors of it.

Methods

The study was conducted as a multicenter survey study. Adolescent cancer patients, who were under remission, were evaluated with structured questionnaires to assess the Ostracism and clinical parameters associated with it. Turkish version of Ostracism Experience Scale for Adolescents (OES-A) and Kutcher adolescent depression scale (KADS) were used.

Results

Between December 2017 and April 2018, 52 patients were evaluated in 4 different cancer centers. Median age was 21 (14-24), 40.4% of them were female and most of them were university student (23, 44.2%). Median OES-A score was 23.5(11.0-41.0). While female sex (28.0 vs 19.0, p = 0.008) and low family income (28.0 vs 21.0, p = 0.02) were associated with more ostracization; patients working full/part time (19.0 vs 25.0, p = 0.01) and university students (19.0 vs 27.0, p = 0.01) were less ostracized. In multivariate analysis, being female was associated with high OES-A scores (OR: 7.8, CI(95%) 1.4-42.9, p = 0.018). Being university student (OR: 0.14, , CI(95%) 0.02- 0.71, p = 0.018) and working (OR: 0.07 , CI(95%) 0.007- 0.7, p = 0.02) were associated with low OES-A scores(Table). Higher OES-A scores were associated with high KADS scores (9.0 vs 7.5, p = 0.16).Table: 1543P

High OES-A Score
CharacteristicsORCI (95%)p
Female7.81.4- 42.90.018
Low income3.20.6-16.30.14
University student0.140.02-0.710.018
Working0.070.007- 0.70.02

Conclusions

It is the first data about ostracism in adolescent cancer patients. OES-A score was higher than the scores of adolescents without cancer. While female adolescent patients were found to be under risk of ostracism, working and being university student were protective against ostracism. Ostracism in adolescent cancer patients should be studied in larger series.

Clinical trial identification

Legal entity responsible for the study

Ali Alkan.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.